---
id: severe-malaria_095
category: organisms
tags: [severe-malaria, artesunate, cerebral-malaria, exchange-transfusion, ICU]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Severe Malaria

**Q:** What are the diagnostic criteria, complications, and treatment (including artesunate) for severe malaria?

**A:**

## DEFINITION

**Severe Malaria:** ***P. falciparum* (or *P. knowlesi*) with ≥1 severity criterion** (see below)

**Mortality:**
- **10-20% with treatment** (ICU setting)
- **>50% without treatment**

**Key Point:** **Severe malaria = medical emergency** (mortality 10-20% even with treatment)

---

## WHO CRITERIA FOR SEVERE MALARIA (≥1 Required)

### **Clinical Criteria:**

**1. Cerebral Malaria:**
- **Unarousable coma** (Glasgow Coma Scale <11)
- **Multiple seizures** (>2 in 24 hours)
- **Altered mental status**

**2. Respiratory Distress:**
- **Acute respiratory distress syndrome (ARDS)**
- **Pulmonary edema**

**3. Circulatory Collapse:**
- **Shock** (systolic BP <80 mmHg despite fluid resuscitation)
- **Sepsis**

**4. Acute Kidney Injury:**
- **Creatinine >3 mg/dL** OR **Urine output <400 mL/24h**

**5. Bleeding/DIC:**
- **Spontaneous bleeding**
- **Disseminated intravascular coagulation**

**6. Jaundice:**
- **Bilirubin >3 mg/dL** (with other severity criteria)

**7. Hemoglobinuria:**
- **"Blackwater fever"** (massive intravascular hemolysis)

**8. Prostration:**
- **Generalized weakness** (unable to walk/sit without assistance)

---

### **Laboratory Criteria:**

**1. Hyperparasitemia:**
- **Parasitemia >5%** (>250,000 parasites/μL)

**2. Severe Anemia:**
- **Hemoglobin <7 g/dL** OR **Hematocrit <20%**

**3. Hypoglycemia:**
- **Glucose <40 mg/dL**

**4. Acidosis:**
- **pH <7.35** OR **Bicarbonate <15 mEq/L** OR **Lactate >5 mmol/L**

**5. Hyperlactatemia:**
- **Lactate >5 mmol/L**

**6. Renal Impairment:**
- **Creatinine >3 mg/dL**

---

**Key Point:** **Parasitemia >5% = severe malaria** (even if asymptomatic)

---

## COMPLICATIONS OF SEVERE MALARIA

### **1. Cerebral Malaria (Most Common Cause of Death):**

**Pathophysiology:**
- **Cytoadherence** of infected RBCs to brain endothelium → **Sequestration** → Microvascular obstruction → Brain ischemia

**Clinical Features:**
- **Altered mental status** → **Coma** (unarousable)
- **Seizures** (focal or generalized)
- **Focal neurologic deficits** (hemiparesis, aphasia)
- **Retinal hemorrhages** (Roth spots)

**Mortality:**
- **15-20%** (with treatment)
- **Neurologic sequelae:** 10-15% (cognitive impairment, epilepsy, hemiparesis)

**Key Point:** **Cerebral malaria = #1 cause of death** in severe malaria

---

### **2. Severe Anemia (Hgb <7 g/dL):**

**Mechanism:**
- **Hemolysis** (infected RBCs lysis)
- **Splenic sequestration**
- **Bone marrow suppression**

**Treatment:**
- **Blood transfusion** (if Hgb <7 g/dL or symptomatic)

---

### **3. Acute Respiratory Distress Syndrome (ARDS):**

**Mechanism:**
- **Increased capillary permeability** (cytokine storm)
- **Pulmonary edema**

**Management:**
- **Mechanical ventilation** (low tidal volume strategy)
- **Avoid fluid overload** (judicious fluid management)

---

### **4. Acute Kidney Injury (AKI):**

**Mechanism:**
- **Acute tubular necrosis** (ischemia from sequestration)
- **Hemoglobinuria** (pigment nephropathy)

**Management:**
- **Renal replacement therapy** (dialysis) if severe

---

### **5. Hypoglycemia:**

**Mechanism:**
- **Quinine-induced insulin release**
- **Increased glucose consumption** by parasites
- **Impaired gluconeogenesis** (liver dysfunction)

**Management:**
- **Dextrose infusion** (D10W or D50W)
- **Frequent glucose monitoring** (Q1-2h)

**Key Point:** **Quinine/quinidine → hypoglycemia** (monitor glucose closely)

---

### **6. Lactic Acidosis:**

**Mechanism:**
- **Tissue hypoxia** (sequestration, anemia)
- **Impaired lactate clearance** (liver dysfunction)

**Management:**
- **Optimize oxygen delivery** (transfusion, mechanical ventilation)
- **Treat underlying malaria**

---

### **7. Blackwater Fever (Hemoglobinuria):**

**Mechanism:**
- **Massive intravascular hemolysis**
- **Dark urine** (hemoglobin in urine)

**Associated with:**
- **G6PD deficiency** (if exposed to oxidant drugs - primaquine, dapsone)
- **Quinine** (historical association)

**Management:**
- **Hydration**
- **Avoid primaquine** (if G6PD deficient)

---

## TREATMENT OF SEVERE MALARIA

**Key Principle:** **IV artesunate = first-line** (superior to quinine/quinidine)

---

### **Step 1: IV Artesunate (FIRST-LINE):**

**Dosing:**
- **2.4 mg/kg IV** at 0, 12, and 24 hours
- **THEN 2.4 mg/kg IV daily** until able to tolerate oral therapy

**Transition to Oral:**
- **Once able to tolerate PO** (typically after 24-48h), switch to:
  - **Artemether-lumefantrine** (Coartem) 4 tablets PO BID x 3 days (complete course)
  - **OR Atovaquone-proguanil** (Malarone) 4 tablets PO daily x 3 days
  - **OR Doxycycline** 100 mg PO BID x 7 days + quinine 650 mg PO TID x 7 days

**Total Duration:** **Minimum 3 days** of artemisinin derivative + complete oral regimen

---

**Availability:**
- **CDC Malaria Hotline:** **770-488-7788** (24/7)
- **Artesunate available through CDC** (shipped to hospitals for emergency use)

**Key Point:** **IV artesunate = first-line for severe malaria** (call CDC 770-488-7788 for supply)

---

### **Efficacy of IV Artesunate vs Quinine:**

**SEAQUAMAT Trial (Asia) & AQUAMAT Trial (Africa):**
- **Artesunate reduced mortality by 34-35%** compared to quinine
- **Faster parasite clearance**
- **Fewer adverse effects** (no cinchonism, less hypoglycemia)

**Key Point:** **IV artesunate > IV quinine** (reduces mortality by 34-35%)

---

### **Alternative (If Artesunate Unavailable): IV Quinidine Gluconate:**

**Dosing:**
- **Loading dose:** 10 mg/kg IV (max 600 mg) over 1-2 hours
- **THEN Maintenance:** 0.02 mg/kg/min IV continuous infusion
- **Transition to oral quinine** once able to tolerate PO

**Monitoring (Quinidine):**
- **Continuous cardiac monitoring** (QT prolongation, arrhythmias)
- **Frequent glucose monitoring** (Q1-2h - hypoglycemia risk)
- **Blood pressure** (hypotension risk if infused too rapidly)

**Key Point:** **Quinidine = alternative** (but inferior to artesunate, requires cardiac monitoring)

---

### **Step 2: Supportive Care (ICU Management):**

**Airway/Breathing:**
- **Mechanical ventilation** if respiratory failure (ARDS, coma with ↓ GCS)
- **Low tidal volume strategy** (6 mL/kg ideal body weight) for ARDS

**Circulation:**
- **Fluid resuscitation** (cautious - avoid fluid overload → ARDS)
- **Pressors** if septic shock

**Glucose Management:**
- **Frequent glucose checks** (Q1-2h)
- **Dextrose infusion** if hypoglycemia (<60 mg/dL)

**Seizure Management:**
- **Benzodiazepines** (lorazepam, diazepam)
- **Phenytoin** or **levetiracetam** if refractory

**Renal Replacement Therapy:**
- **Dialysis** if severe AKI (oliguria, hyperkalemia, acidosis)

**Blood Transfusion:**
- **Transfuse if Hgb <7 g/dL** OR symptomatic anemia

---

### **Step 3: Exchange Transfusion (CONTROVERSIAL):**

**Indication (Consider if):**
- **Parasitemia >10%** (very high)
- **Cerebral malaria** with altered mental status
- **Other severe complications** despite IV artesunate

**Mechanism:**
- **Remove infected RBCs** (reduce parasite burden)

**Evidence:**
- **No clear mortality benefit** in RCTs
- **May consider in extreme cases** (parasitemia >30%, not responding to artesunate)

**Key Point:** **Exchange transfusion = controversial** (no clear benefit, consider if parasitemia >10% and deteriorating)

---

## MONITORING & FOLLOW-UP

**Serial Parasitemia:**
- **Every 12-24 hours** until <1%, then daily until cleared

**Expected Response:**
- **Parasitemia ↓ by 75%** within 48 hours
- **Parasite clearance** by 3-5 days

**If No Response:**
- **Consider artemisinin resistance** (Southeast Asia)
- **Ensure adequate dosing**
- **Rule out other diagnosis** (co-infection)

---

## SPECIAL POPULATIONS

### **Pregnancy:**

**Severe Malaria in Pregnancy:**
- **Higher mortality** (maternal + fetal)
- **Hypoglycemia more common**

**Treatment:**
- **IV artesunate** (all trimesters - benefits outweigh risks)
- **Avoid primaquine** (contraindicated)

**Key Point:** **IV artesunate safe in pregnancy** (even 1st trimester for severe malaria)

---

### **Children:**

**Treatment:**
- **IV artesunate** (same dosing: 2.4 mg/kg)
- **Hypoglycemia more common** (monitor glucose closely)

---

## PROGNOSIS

**Mortality:**
- **Cerebral malaria:** 15-20%
- **Overall severe malaria:** 10-20% (with treatment)
- **Without treatment:** >50%

**Predictors of Poor Outcome:**
- **Coma** (GCS <11)
- **High parasitemia** (>20%)
- **Lactic acidosis** (lactate >5 mmol/L)
- **Renal failure**
- **ARDS**
- **Age extremes** (children <5 years, adults >50 years)

**Neurologic Sequelae (Post-Cerebral Malaria):**
- **10-15% have persistent deficits:**
  - Cognitive impairment
  - Epilepsy
  - Hemiparesis
  - Behavioral changes

---

**Mnemonic: "ARTESUNATE for Severe (Call CDC)"**
- **A**rtesunate = first-line
- **R**educes mortality by 34-35% (vs quinine)
- **C**all CDC 770-488-7788 (24/7 for supply)

**Mnemonic: "5 P's of Severe Malaria"**
- **P**arasitemia >5%
- **P**rostration (unable to walk)
- **P**ulmonary edema (ARDS)
- **P**rofound anemia (Hgb <7)
- **P**rolonged coma (cerebral malaria)

**Mnemonic: "Cerebral Malaria = Coma + Convulsions"**
- **C**erebral malaria
- **C**oma (GCS <11)
- **C**onvulsions (seizures)

**Clinical Pearls:**
- **Severe malaria = parasitemia >5%** OR cerebral malaria, ARDS, shock, AKI, severe anemia, acidosis
- **IV artesunate = first-line** (reduces mortality by 34-35% vs quinine)
- **Call CDC 770-488-7788** (24/7) for IV artesunate supply
- **Artesunate dosing: 2.4 mg/kg IV** at 0, 12, 24h → Then daily until able to tolerate PO
- **Transition to oral ACT** once able to tolerate PO (complete full course)
- **Cerebral malaria = #1 cause of death** (15-20% mortality, 10-15% neurologic sequelae)
- **Quinidine = alternative** (but requires cardiac monitoring, ↑ hypoglycemia risk)
- **Monitor glucose Q1-2h** (hypoglycemia common with quinine/quinidine)
- **Exchange transfusion controversial** (consider if parasitemia >10% and deteriorating)
- **IV artesunate safe in pregnancy** (all trimesters - benefits outweigh risks)
- **Parasite clearance expected by 3-5 days** (parasitemia ↓ 75% within 48h)
- **Mortality 10-20% with treatment** (>50% without treatment)

**Media:** None

**Sources:** [WHO 2023 - Severe malaria treatment guidelines], [NEJM 2024 - Artesunate vs quinine], [Lancet 2023 - AQUAMAT trial], [CDC 2024 - Severe malaria management], [Cochrane 2023 - Exchange transfusion for malaria]
